4D Pharma logo

DDDD - 4D Pharma Share Price

123p 5.0  4.2%

Last Trade - 20/01/21

Sector
Healthcare
Size
Small Cap
Market Cap £155.0m
Enterprise Value £146.1m
Revenue £486k
Position in Universe 883rd / 1804
Bullish
Bearish
Unlock DDDD Revenue
Momentum
Relative Strength (%)
1m +7.75%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -35.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.21 15.4
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, 4d Pharma PLCrevenues increased from £0K to £275K. Net loss increased14% to £13.7M. Revenues reflect an increase in demand forthe Company's products and services due to favorable marketconditions. Higher net loss reflects Administrativeexpenses increase of 88% to £4.4M (expense), Research anddevelopment costs increase of 15% to £12.4M (expense),Finance income decrease of 92% to £5K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for DDDD
Graphical History

Revenue

DDDD Revenue Unlock DDDD Revenue

Net Income

DDDD Net Income Unlock DDDD Revenue

Normalised EPS

DDDD Normalised EPS Unlock DDDD Revenue

PE Ratio Range

DDDD PE Ratio Range Unlock DDDD Revenue

Dividend Yield Range

DDDD Dividend Yield Range Unlock DDDD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
DDDD EPS Forecasts Unlock DDDD Revenue
Profile Summary

4D pharma plc (4D), formerly Schosween 18 Limited, is a United Kingdom-based pharmaceutical company focusing on developing various projects targeting new therapeutic areas. The principal activity of the Company is research and development of pharmaceutical products in new live biotherapeutic areas. The Company has developed its research to build MicroRx, which is a discovery methodology that is able to rationally select those bacteria that have a precise and evolved therapeutic effect. Its MicroRx methodology offers a pipeline of approximately 10 therapeutic programs covering autoimmune diseases, central nervous system (CNS) disorders and cancer. The Company uses MicroRx to develop its programs into the clinic and has approximately two programs in patient trials. The Company focuses on immune conditions, such as pediatric Crohn's, pediatric colitis and irritable bowel syndrome.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated January 10, 2014
Public Since February 18, 2014
No. of Shareholders: n/a
No. of Employees: 127
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE Aim All Share ,
Exchange London Stock Exchange (AIM)
Shares in Issue 131,392,242
Free Float (0.0%)
Eligible for
ISAs
SIPPs
DDDD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for DDDD
Upcoming Events for DDDD
Frequently Asked Questions for 4D Pharma
What is the 4D Pharma share price?

As of 20/01/21, shares in 4D Pharma are trading at 123p, giving the company a market capitalisation of £155.0m. This share price information is delayed by 15 minutes.

How has the 4D Pharma share price performed this year?

Shares in 4D Pharma are currently trading at 123p and the price has moved by 18% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the 4D Pharma price has moved by 31.2% over the past year.

What are the analyst and broker recommendations for 4D Pharma?

Of the analysts with advisory recommendations for 4D Pharma, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for 4D Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will 4D Pharma next release its financial results?

4D Pharma is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the 4D Pharma dividend yield?

4D Pharma does not currently pay a dividend.

Does 4D Pharma pay a dividend?

4D Pharma does not currently pay a dividend.

When does 4D Pharma next pay dividends?

4D Pharma does not currently pay a dividend.

How do I buy 4D Pharma shares?

To buy shares in 4D Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of 4D Pharma?

Shares in 4D Pharma are currently trading at 123p, giving the company a market capitalisation of £155.0m.

Where are 4D Pharma shares listed? Where are 4D Pharma shares listed?

Here are the trading details for 4D Pharma:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: DDDD
What kind of share is 4D Pharma?

Based on an overall assessment of its quality, value and momentum, 4D Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a 4D Pharma share price forecast 2021?

Shares in 4D Pharma are currently priced at 123p. At that level they are trading at 0.263% discount to the analyst consensus target price of 123.32.

Analysts covering 4D Pharma currently have a consensus Earnings Per Share (EPS) forecast of -0.194 for the next financial year.

How can I tell whether the 4D Pharma share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4D Pharma. Over the past six months, the relative strength of its shares against the market has been 0.122k%. At the current price of 123p, shares in 4D Pharma are trading at 38.44% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the 4D Pharma PE Ratio?

We were not able to find PE ratio data for 4D Pharma.

Who are the key directors of 4D Pharma?

4D Pharma's management team is headed by:

David Norwood - NED
Duncan Peyton - CEO
Alexander Stevenson - CSO
Edgardo Baracchini - NID
Axel Glasmacher - NEC
Sandy Macrae - NID
Katrin Rupalla - NID
Who are the major shareholders of 4D Pharma?

Here are the top five shareholders of 4D Pharma based on the size of their shareholding:

South Ocean Capital Management Corporation
Percentage owned: 10.99% (14.4m shares)
Peyton (Duncan Joseph) Individual Investor
Percentage owned: 5.93% (7.79m shares)
Stevenson (Alexander James) Individual Investor
Percentage owned: 5.9% (7.75m shares)
Merck Sharp & Dohme Corporation Corporation
Percentage owned: 5.83% (7.66m shares)
Hargreaves Lansdown Asset Management Limited Investment Advisor
Percentage owned: 5.18% (6.81m shares)
Similar to DDDD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.